Authors: ten Berge, RL Oudejans, JJ Dukers, DF Meijer, JWR Ossenkoppele, GJ Meijer, CJLM

Citation: Rl. Ten Berge et al., Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker, LEUKEMIA, 15(3), 2001, pp. 458-464

Authors: Brink, AATP ten Berge, RL van den Brule, AJC Willemze, R Chott, A Meijer, CJLM

Citation: Aatp. Brink et al., Epstein-Barr virus is present in neoplastic cytotoxic T cells in extranodal, and predominantly in B cells in nodal T non-Hodgkin lymphomas, J PATHOLOGY, 191(4), 2000, pp. 400-406

Authors: ten Berge, RL Oudejans, JJ Ossenkoppele, GJ Pulford, K Willemze, R Falini, B Chott, A Meijer, CJLM

Citation: Rl. Ten Berge et al., ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occursbefore dissemination, J CLIN PATH, 53(6), 2000, pp. 445-450

Authors: Dukers, DF ten Berge, RL Oudejans, JJ Pulford, K Hayes, D Misere, JFMM Ossenkoppele, GJ Jaspars, LH Willemze, R Meijer, CJLM

Citation: Df. Dukers et al., A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas, J CLIN PATH, 52(2), 1999, pp. 129-136

Authors: ten Berge, RL Dukers, DF Oudejans, JJ Pulford, K Ossenkoppele, GJ de Jong, D Misere, JFMM Meijer, CJLM

Citation: Rl. Ten Berge et al., Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma, BLOOD, 93(8), 1999, pp. 2688-2696

Authors: Oudejans, JJ Dukers, DF ten Berge, RL Meijer, CJLM

Citation: Jj. Oudejans et al., Untitled, AM J PATH, 155(1), 1999, pp. 325-325